The guidance describes how FDA plans
to work with applicants and sponsors to achieve expedited
development and rapid review of new drugs or biological products
intended to treat serious or life-threatening conditions and that
demonstrate the potential to address unmet medical needs for the
condition. A sponsor or applicant seeking to have a drug or
biological product designated as one in a fast track drug
development program may submit a request for fast track designation
as an amendment to an IND or as a supplement to an application.
After FDA makes a fast track designation, the sponsor or applicant
may submit a pre-meeting package which may include additional
information supporting a request to participate in certain fast
track programs.
The adjustment in burden from
14,780 to 15,700 hours is the result of an increase in the number
of designation requests and premeeting packages submitted over the
past three years.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.